 | • レポートコード：MRC23Q36044 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、89ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のギランバレー症候群治療市場について調査・分析し、世界のギランバレー症候群治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（免疫グロブリン療法、血漿交換療法（プラズマフェレーシス））、用途別セグメント分析（病院、クリニック、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、CSL Limited、Grifols S A、Octapharma AG、Kedrion Biopharma Inc、Biotest AGなどが含まれています。世界のギランバレー症候群治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ギランバレー症候群治療市場規模を推定する際に考慮しました。本レポートは、ギランバレー症候群治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ギランバレー症候群治療に関するビジネス上の意思決定に役立てることを目的としています。 ・ギランバレー症候群治療市場の概要 - ギランバレー症候群治療のタイプ別セグメント - 世界のギランバレー症候群治療市場規模：タイプ別分析（免疫グロブリン療法、血漿交換療法（プラズマフェレーシス）） - ギランバレー症候群治療の用途別セグメント - 世界のギランバレー症候群治療市場規模：用途別分析（病院、クリニック、その他） - 世界のギランバレー症候群治療市場規模予測（2018年-2029年） ・ギランバレー症候群治療市場の成長トレンド - ギランバレー症候群治療の地域別市場規模（2018年-2029年） - ギランバレー症候群治療市場ダイナミクス - ギランバレー症候群治療の業界動向 - ギランバレー症候群治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：免疫グロブリン療法、血漿交換療法（プラズマフェレーシス） - 世界のギランバレー症候群治療のタイプ別市場規模（2018年-2023年） - 世界のギランバレー症候群治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、クリニック、その他 - 世界のギランバレー症候群治療の用途別市場規模（2018年-2023年） - 世界のギランバレー症候群治療の用途別市場規模（2024年-2029年） ・ギランバレー症候群治療の地域別市場規模 - 北米のギランバレー症候群治療市場規模（2018年-2029年） - アメリカのギランバレー症候群治療市場規模（2018年-2029年） - ヨーロッパのギランバレー症候群治療市場規模（2018年-2029年） - アジア太平洋のギランバレー症候群治療市場規模（2018年-2029年） - 中国のギランバレー症候群治療市場規模（2018年-2029年） - 日本のギランバレー症候群治療市場規模（2018年-2029年） - 韓国のギランバレー症候群治療市場規模（2018年-2029年） - インドのギランバレー症候群治療市場規模（2018年-2029年） - オーストラリアのギランバレー症候群治療市場規模（2018年-2029年） - 中南米のギランバレー症候群治療市場規模（2018年-2029年） - 中東・アフリカのギランバレー症候群治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 CSL Limited、Grifols S A、Octapharma AG、Kedrion Biopharma Inc、Biotest AG ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Guillain-Barre Syndrome Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Guillain-Barre Syndrome Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Guillain-Barre Syndrome Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Guillain-Barre Syndrome Treatment in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Guillain-Barre Syndrome Treatment include CSL Limited, Grifols S A, Octapharma AG, Kedrion Biopharma Inc and Biotest AG, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Guillain-Barre Syndrome Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Guillain-Barre Syndrome Treatment.
The Guillain-Barre Syndrome Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Guillain-Barre Syndrome Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Guillain-Barre Syndrome Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
CSL Limited
Grifols S A
Octapharma AG
Kedrion Biopharma Inc
Biotest AG
Segment by Type
Immunoglobulin Therapy
Plasma Exchange (Plasmapheresis)
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Guillain-Barre Syndrome Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Guillain-Barre Syndrome Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Immunoglobulin Therapy
1.2.3 Plasma Exchange (Plasmapheresis)
1.3 Market by Application
1.3.1 Global Guillain-Barre Syndrome Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Guillain-Barre Syndrome Treatment Market Perspective (2018-2029)
2.2 Guillain-Barre Syndrome Treatment Growth Trends by Region
2.2.1 Global Guillain-Barre Syndrome Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Guillain-Barre Syndrome Treatment Historic Market Size by Region (2018-2023)
2.2.3 Guillain-Barre Syndrome Treatment Forecasted Market Size by Region (2024-2029)
2.3 Guillain-Barre Syndrome Treatment Market Dynamics
2.3.1 Guillain-Barre Syndrome Treatment Industry Trends
2.3.2 Guillain-Barre Syndrome Treatment Market Drivers
2.3.3 Guillain-Barre Syndrome Treatment Market Challenges
2.3.4 Guillain-Barre Syndrome Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Guillain-Barre Syndrome Treatment Players by Revenue
3.1.1 Global Top Guillain-Barre Syndrome Treatment Players by Revenue (2018-2023)
3.1.2 Global Guillain-Barre Syndrome Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Guillain-Barre Syndrome Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Guillain-Barre Syndrome Treatment Revenue
3.4 Global Guillain-Barre Syndrome Treatment Market Concentration Ratio
3.4.1 Global Guillain-Barre Syndrome Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Guillain-Barre Syndrome Treatment Revenue in 2022
3.5 Guillain-Barre Syndrome Treatment Key Players Head office and Area Served
3.6 Key Players Guillain-Barre Syndrome Treatment Product Solution and Service
3.7 Date of Enter into Guillain-Barre Syndrome Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Guillain-Barre Syndrome Treatment Breakdown Data by Type
4.1 Global Guillain-Barre Syndrome Treatment Historic Market Size by Type (2018-2023)
4.2 Global Guillain-Barre Syndrome Treatment Forecasted Market Size by Type (2024-2029)
5 Guillain-Barre Syndrome Treatment Breakdown Data by Application
5.1 Global Guillain-Barre Syndrome Treatment Historic Market Size by Application (2018-2023)
5.2 Global Guillain-Barre Syndrome Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Guillain-Barre Syndrome Treatment Market Size (2018-2029)
6.2 North America Guillain-Barre Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Guillain-Barre Syndrome Treatment Market Size by Country (2018-2023)
6.4 North America Guillain-Barre Syndrome Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Guillain-Barre Syndrome Treatment Market Size (2018-2029)
7.2 Europe Guillain-Barre Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Guillain-Barre Syndrome Treatment Market Size by Country (2018-2023)
7.4 Europe Guillain-Barre Syndrome Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Guillain-Barre Syndrome Treatment Market Size (2018-2029)
8.2 Asia-Pacific Guillain-Barre Syndrome Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Guillain-Barre Syndrome Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Guillain-Barre Syndrome Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Guillain-Barre Syndrome Treatment Market Size (2018-2029)
9.2 Latin America Guillain-Barre Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Guillain-Barre Syndrome Treatment Market Size by Country (2018-2023)
9.4 Latin America Guillain-Barre Syndrome Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Guillain-Barre Syndrome Treatment Market Size (2018-2029)
10.2 Middle East & Africa Guillain-Barre Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Guillain-Barre Syndrome Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Guillain-Barre Syndrome Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 CSL Limited
11.1.1 CSL Limited Company Detail
11.1.2 CSL Limited Business Overview
11.1.3 CSL Limited Guillain-Barre Syndrome Treatment Introduction
11.1.4 CSL Limited Revenue in Guillain-Barre Syndrome Treatment Business (2018-2023)
11.1.5 CSL Limited Recent Development
11.2 Grifols S A
11.2.1 Grifols S A Company Detail
11.2.2 Grifols S A Business Overview
11.2.3 Grifols S A Guillain-Barre Syndrome Treatment Introduction
11.2.4 Grifols S A Revenue in Guillain-Barre Syndrome Treatment Business (2018-2023)
11.2.5 Grifols S A Recent Development
11.3 Octapharma AG
11.3.1 Octapharma AG Company Detail
11.3.2 Octapharma AG Business Overview
11.3.3 Octapharma AG Guillain-Barre Syndrome Treatment Introduction
11.3.4 Octapharma AG Revenue in Guillain-Barre Syndrome Treatment Business (2018-2023)
11.3.5 Octapharma AG Recent Development
11.4 Kedrion Biopharma Inc
11.4.1 Kedrion Biopharma Inc Company Detail
11.4.2 Kedrion Biopharma Inc Business Overview
11.4.3 Kedrion Biopharma Inc Guillain-Barre Syndrome Treatment Introduction
11.4.4 Kedrion Biopharma Inc Revenue in Guillain-Barre Syndrome Treatment Business (2018-2023)
11.4.5 Kedrion Biopharma Inc Recent Development
11.5 Biotest AG
11.5.1 Biotest AG Company Detail
11.5.2 Biotest AG Business Overview
11.5.3 Biotest AG Guillain-Barre Syndrome Treatment Introduction
11.5.4 Biotest AG Revenue in Guillain-Barre Syndrome Treatment Business (2018-2023)
11.5.5 Biotest AG Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details